World Acute Ischemic Stroke Diagnosis and Treatment Market - Opportunities and Forecasts, 2020-2027
|
A01121
|
Pages: NA
|
Jul 2020 |
4661 Views
|
|
|
|
Author(s) :
NA
|
Tables: NA
|
Charts: NA
|
Formats*:
|
|
COVID-19
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the World Acute Ischemic Stroke Diagnosis And Treatment Market
Request Now !Ischemic stroke is caused by a dysfunction in the supply of blood to the brain due to emboli, thrombus or atherosclerosis occurring in cerebral arteries. According to a World Health Organization (WHO) estimate, around 17 million people die every year due to cardiovascular diseases. Heart attacks and strokes respectively account for the highest number of deaths due to cardiovascular diseases, globally. The statistics of the Centres for Disease Control and Prevention suggest that about 87% of all strokes are ischemic strokes. Stroke is one of the leading cause of long term disability, occurring at a higher rate in the old age population. Moreover, stroke leads to 1 out of every 20 deaths, costing around $34 billion to U.S. annually. Higher rates of mortality associated with strokes highlight an impending need for innovative drugs and diagnostic devices.
The two major factors propelling the growth of the acute ischemic stroke diagnosis and treatment market are; large patient pools and a concerning rise in population at a higher risk of developing stroke in the near future. Rising incidence of diabetes along with heavy tobacco users and an increase in the ageing population are significant factors that determine the market growth. However, the high cost of treatment, lack of transparent reimbursement policies, and limited availability of expertise; are likely to restrict the market growth.
The global ischemic stroke diagnosis and treatment market is segmented on the basis of type and geography. According to type, the market is segmented into, diagnostics and therapeutics. The diagnostic market is further segmented into Computed Tomography Scan (CT scan), Magnetic Resonance Imaging (MRI), Carotid Ultrasound, Cerebral Angiography, Electrocardiography, Echocardiography and Blood tests. The therapeutic market further segments into Tissue Plasminogen Activator Anticoagulant, Antiplatelet and Antihypertensive. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific, and LAMEA.
New Product launches and collaborations are some of the key strategies adopted by leading industry players. In March, 2015, FDA approved WATCHMAN, a left atrial appendage closure device designed to prevent stroke in patients with atrial fibrillation. Silk Road Medical, Inc. has launched an Anti-Stroke Enroute Device, a transcarotid neuroprotection system, designed to access the common carotid artery through a minimally invasive technique. NeuroVive Pharmaceutical AB, entered into collaboration with BBB Therapeutics, for development of the NVP014 drug candidate used in the treatment of ischemic strokes.
The companies profiled in this report include, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Cordis Corporation, Koninklijke Philips N.V., GE Healthcare, Siemens AG, Stryker Corporation, Genentech, Inc. and Merck & Co., Inc.
KEY MARKET BENEFITS:
- Comprehensive analysis of factors that drive and restrict the growth of the global acute ischemic stroke diagnosis and treatment market is provided
- The report provides a comprehensive analysis of the current market and estimations through 20142020, which would enable the stakeholders to capitalize on prevailing market opportunities
- An in-depth analysis of the key segments of the market demonstrate the types of therapeutics along with the diagnostics that currently used in the acute ischemic stroke market
- SWOT analysis highlights the internal environment of leading companies for effective strategy formulation
- The acute ischemic stroke diagnosis and treatment market scenario is comprehensively analysed in accordance to the key regions
- Competitive intelligence highlights the business practises followed by leading market players across geographies
KEY MARKET SEGMENTS:
The global acute ischemic stroke diagnosis and treatment market is segmented below:
Acute Ischemic Stroke Diagnosis and Treatment Market By Type
- Diagnostics
- Computed Tomography (CT)
- Magnetic resonance imaging (MRI)
- Carotid Ultrasound
- Cerebral Angiography
- Electrocardiography
- Echocardiography
- Others
- Therapeutics
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
Acute Ischemic Stroke Diagnosis and Treatment Market By Geography
- North America
- Europe
- Asia-Pacific
- LAMEA
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH APPLICATIONOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4.
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4 ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. DIAGNOSTICS
4.2.1. Key market trends, growth factors & opportunities
4.2.2. Market size and forecast, by ype
4.2.2.1. Computed Tomography (CT)
4.2.2.1.1. Market size and forecast
4.2.2.2. Magnetic Resonance Imaging (MRI)
4.2.2.2.1. Market size and forecast
4.2.2.3. Carotid Ultrasound
4.2.2.3.1. Market size and forecast
4.2.2.4. Cerebral Angiography
4.2.2.4.1. Market size and forecast
4.2.2.5. Electrocardiography
4.2.2.5.1. Market size and forecast
4.2.2.6. Echocardiography
4.2.2.6.1. Market size and forecast
4.2.2.7. Others
4.2.2.7.1. Market size and forecast
4.2.3. Market size and forecast , by region
4.2.4. Market analysis, by country
4.3. TREATMENT
4.3.1. Key market trends, growth factors & opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Therapeutics
4.3.2.1.1. Tissue Plasminogen Activator
4.3.2.1.1.1. Market size and forecast
4.3.2.1.2. Anticoagulant
4.3.2.1.2.1. Market size and forecast
4.3.2.1.3. Antiplatelate
4.3.2.1.3.1. Market size and forecast
4.3.2.1.4. Antihypertensive
4.3.2.1.4.1. Market size and forecast
4.3.2.2. Surgery devices
4.3.2.2.1. Market size and forecast
4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country
CHAPTER 5 ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY REGION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. North America market size and forecast, by country
5.2.2.1. U.S. acute ischemic stroke diagnosis and treatment market size and forecast
5.2.2.2. Canada acute ischemic stroke diagnosis and treatment market size and forecast
5.2.2.3. Mexico acute ischemic stroke diagnosis and treatment market size and forecast
5.2.3. North America acute ischemic stroke diagnosis and treatment market, by type
5.3. EUROPE
5.3.1. Key market trends
5.3.2. Europe market size and forecast, by country
5.3.2.1. Germany acute ischemic stroke diagnosis and treatment market size and forecast
5.3.2.2. France acute ischemic stroke diagnosis and treatment market size and forecast
5.3.2.3. UK acute ischemic stroke diagnosis and treatment market size and forecast
5.3.2.4. Italy. acute ischemic stroke diagnosis and treatment market size and forecast
5.3.2.5. Spain acute ischemic stroke diagnosis and treatment market size and forecast
5.3.2.6. Rest of Europe acute ischemic stroke diagnosis and treatment market size and forecast
5.3.3. Europe acute ischemic stroke diagnosis and treatment market, by type
5.4. ASIA-PACIFIC
5.4.1. Key market trends
5.4.2. Asia-Pacific market size and forecast, by country
5.4.2.1. Japan acute ischemic stroke diagnosis and treatment market size and forecast
5.4.2.2. China acute ischemic stroke diagnosis and treatment market size and forecast
5.4.2.3. Australia acute ischemic stroke diagnosis and treatment market size and forecast
5.4.2.4. India. acute ischemic stroke diagnosis and treatment market size and forecast
5.4.2.5. South Korea acute ischemic stroke diagnosis and treatment market size and forecast
5.4.2.6. Rest of Asia-Pacific acute ischemic stroke diagnosis and treatment market size and forecast
5.4.3. Asia-Pacific acute ischemic stroke diagnosis and treatment market, by type
5.5. LAMEA
5.5.1. Key market trends
5.5.2. LAMEA market size and forecast, by country
5.5.2.1. Brazil acute ischemic stroke diagnosis and treatment market size and forecast
5.5.2.2. Saudi Arabia acute ischemic stroke diagnosis and treatment market size and forecast
5.5.2.3. South Africa acute ischemic stroke diagnosis and treatment market size and forecast
5.5.2.4. Rest of LAMEA. acute ischemic stroke diagnosis and treatment market size and forecast
5.5.3. LAMEA acute ischemic stroke diagnosis and treatment market, by type
CHAPTER 6 COMPANY PROFILES
6.1. ABBOTT LABORATORIES
6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments
6.2. MEDTRONIC PLC
6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments
6.3. BOSTON SCIENTIFIC CORPORATION
6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments
6.4. CORDIS CORPORATION
6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments
6.5. KONINKLIJKE PHILIPS N.V.
6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments
6.6. GE HEALTHCARE
6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments
6.7. SIEMENS AG
6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments
6.8. STRYKER CORPORATION
6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments
6.9. GENENTECH, INC.
6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments
6.10. MERCK & CO., INC.
6.10.1. Operating business segments
6.10.2. Business performance
6.10.3. Key strategic moves and developments
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
REQUEST TOC/SAMPLE
Purchase Full Report of
World Acute Ischemic Stroke Diagnosis and Treatment Market-
Opportunities and Forecasts, 2020-2027
- Online Only
-
$3,456$3,110 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
-
$3,840$3,456 - Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
-
$5,769$5,192 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
-
$6,450$5,805 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF -
$8,995$8,096 - Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Membership
- $0.00
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading.
Buy Now
This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.